Inspired by the remarkable in vitro anticancer activity of IR‐TAM@Alb and its exceptional immune reactivation capacity in vivo, the 4T1 tumor model was then established to further evaluate the synergistic therapeutic effect of IR‐TAM@Alb and RT (Figure 5). The gene discussed is ALB; the disease is neoplasm.